Author(s):
R. Karthikeyan, V. Vijayan, S. Shanmuganathan, P. Vijayarajkumar, R.Saravanan, S. Brito Raj
Email(s):
Email ID Not Available
DOI:
10.52711/0974-360X.2025.00666 
Address:
R. Karthikeyan1*, V. Vijayan 1, S. Shanmuganathan1, P. Vijayarajkumar2, R.Saravanan3, S. Brito Raj4
1School of Pharmacy, Sri Balaji Vidyapeeth, SBV Campus, Pillayarkuppam, Puducherry, India.
2Faculty of Pharmaceutical Sciences, UCSI University, UCSI Heights, 56000 Kuala Lumpur, Malaysia.
3Faculty of Pharmacy, Bharath Institute of Higher Education and Research, Chennai-73. India.
4School of Pharmacy, Dhanalakshmi Srinivasan University, Trichy-621112.
*Corresponding Author
Published In:
Volume - 18,
Issue - 10,
Year - 2025
ABSTRACT:
Background: The outbreak of SARS-COV-2 in 2019 triggered a pandemic scenario worldwide, claiming 6.4 million lives. Favipiravir (FAV) is an RdRp inhibitor, recommended as a treatment for SARS-CoV-2 infection, with a half-life of 2-5.5 hours, which is very short. Hence, to increase the half-life and bioavailability this study aimed. Objectives: Thus, the current study's goal was to create Nanoparticles as favipiravir-loaded PLGA NPs. Methodology: The nanoprecipitation technique was employed to create the favipiravir-loaded nanoparticles. Results: The nanoparticles size was established to be 175.6 2 nm and an EE more than 70 0.5%. NPs had a PDI of 0.130 and an electro kinetic potential indicating homogeneity and stability of 17.1 mV. Discussion: DSC, XRD analyses revealed no interaction between FAV and the excipients. The Morphology and the surface of the particles were revealed to be spherical and smooth by SEM. A dissolution investigation revealed that FAV was released more slowly (24h) and drug loaded NPs were shown (32h). Conclusion: Therefore, it could be an effective product for combating SARS-CoV-2 infection due to its high patient adherence.
Cite this article:
R. Karthikeyan, V. Vijayan, S. Shanmuganathan, P. Vijayarajkumar, R.Saravanan, S. Brito Raj. RNA - Dependent RNA - Polymerase Inhibitor Loaded Mucoadhesive PLGA Nanoparticles: A Study On Formulation and Evaluation of Dry Powder Inhaler. Research Journal of Pharmacy and Technology. 2025;18(10):4635-0. doi: 10.52711/0974-360X.2025.00666
Cite(Electronic):
R. Karthikeyan, V. Vijayan, S. Shanmuganathan, P. Vijayarajkumar, R.Saravanan, S. Brito Raj. RNA - Dependent RNA - Polymerase Inhibitor Loaded Mucoadhesive PLGA Nanoparticles: A Study On Formulation and Evaluation of Dry Powder Inhaler. Research Journal of Pharmacy and Technology. 2025;18(10):4635-0. doi: 10.52711/0974-360X.2025.00666 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-10-5
7. REFERENCES:
1. Mayur S. Jain, Shashikant D. Barhate. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19: A Review. 10.5958/2231-5691.2021.00008.3
2. Yogita R. Indalkar, Nayana V. Pimpodkar, Puja S. Gaikwad, Anita S. Godase. A Comprehensive Review on Biodegradable Polymers. Asian J. Res. Pharm. Sci. 2016; 6(2): 65-76
3. Dange YD, Honmane SM, Patil PA, Gaikwad UT, Jadge DR. Nanotechnology, Nanodevice Drug Delivery System: A Review. Asian J. Pharm. Tech. 2017; 7(2): 63-71.
4. Guo X et al., PLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases. Int J Mol Sci. 2023 Feb 22;24(5):4333.
5. Hurgobin B, de Jong E, Bosco A. Insights into respiratory disease through bioinformatics. Respirology. 2018; 23(12): 1117-1126.
6. Takeuchi, H., Yamamoto, H., Kawashima, Y., 2001. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47. https://doi.org/10.1016/S0169-409X(00)00120-4
7. Saudagar R. B., Sarika V. Khandbahale. In-Situ Nasal Gel- A Review. Asian J. Res. Pharm. Sci. 2017; 7(1): 23-32.
8. Nuha R et al., Simultaneous Formulation, Evaluation and estimation of controlled release of NSAID Drug. Asian J. Pharm. Ana. 2017; 7(3): 176-184.
9. Kishore D et al., (2021). Development and validation of a new hplc bioanalytical internal standard method for the analysis of Favipiravirin human plasma. Rasayan Journal of Chemistry. 14. https://doi.org/10.31788/RJC.2021.1446373
10. Li, Y et al., (2022). Transformation of nanoparticles into compacts: A study on PLGA and celecoxib nanoparticles. Int J Pharm. 611. https://doi.org/10.1016/j.ijpharm.2021.121278
11. S. S.Chandana, R. Ravichandra Babu. Method Development and Validation of Valsartan and Its Impurities by High Performance Liquid Chromatography. Asian J. Pharm. Ana. 2017; 7(2): 87-92.
12. Smita S. Aher, Sagar T. Malsane, R. B. Saudagar. Nanosuspension: An Overview. Asian J. Res. Pharm. Sci. 2017; 7(2):81-86.
13. Amin, M K et al.,(2022). Enhancing Stability and Mucoadhesive Properties of Chitosan Nanoparticles by Surface Modification with Sodium Alginate and Polyethylene Glycol for Potential Oral Mucosa Vaccine Delivery. Mar Drugs 20. https://doi.org/10.3390/md20030156.
14. Diaz-Fuentes, G., Hashmi, H.R.T., Venkatram, S., 2016. Perioperative Evaluation of Patients with Pulmonary Conditions Undergoing Non-Cardiothoracic Surgery. Health Serv Insights. https://doi.org/10.4137/HSI.S40541
15. Prashant S. Wake, M. D. Kshirsagar. Design and Characterization of Solid Lipid Nanoparticle Based Transdermal Drug Delivery System. Asian J. Res. Pharm. Sci. 2017; 7(2): 87-91.
16. Jhansipriya V et al., Chitosan Based Sustained Release Mucoadhesive Buccal Patches Containing Amlodipine Besylate (AMB). Asian J. Res. Pharm. Sci. 2017; 7(2): 97-104.
17. Lepeltier, E., Bourgaux, C., Couvreur, P., 2014. Nanoprecipitation and the “Ouzo effect”: Application to drug delivery devices. Adv Drug Deliv Rev. https://doi.org/10.1016/j.addr.2013.12.009
18. Rohan R. Vakhariya, Swati S. Talokar, V. R. Salunkhe, C. S. Magdum. Formulation Development and Optimization of Simvastatin Loaded Solid Lipid Nanoparticles. Asian J. Res. Pharm. Sci. 2017; 7(1): 49-52.
19. Ghose D et al.,(2021). QbD-based formulation optimization and characterization of polymeric nanoparticles of cinacalcet hydrochloride with improved biopharmaceutical attributes. Turk J Pharm Sci 18. https://doi.org/10.4274/tjps.galenos.2020.08522
20. Sahakijpijarn S et al.,(2021). In vivo pharmacokinetic study of Favipiravir dry powder for inhalation in hamsters. Int J Pharm X 3. https://doi.org/10.1016/j.ijpx.2021.100073
21. Whittemore JH et al.,(2015). Investigation of ouzo effect colloid formation via organosilica nanoparticles. Colloid Polym Sci 293. https://doi.org/10.1007/s00396-015-3657-x
22. Phalguna Yadagiri, Rama Rao Korapati. Formulation, Characterization and In Vitro Evaluation of Lamivudine Microspheres. Asian J. Res. Pharm. Sci. 2016; 6(4): 235-239.
23. He Y et al.,(2019). Influence of probe-sonication process on drug entrapment efficiency of liposomes loaded with a hydrophobic drug. International Journal of Polymeric Materials and Polymeric Biomaterials 68. https://doi.org/10.1080/00914037.2018.1434651
24. Guadarrama-Escobar OR et al.,(2021). Development, characterization, optimization, and in vivo evaluation of methacrylic acid–ethyl acrylate copolymer nanoparticles loaded with glibenclamide in diabetic rats for oral administration. Pharmaceutics 13. https://doi.org/10.3390/pharmaceutics13122023
25. Smita S. Aher, Vaishali D. Sangale, Ravindra B. Saudagar. Mucoadhesive Formulations for Buccal Mucosa. Asian J. Res. Pharm. Sci. 2016; 6(3):146-152.
26. Sankar R et al.,(2013). Development and characterization of gastroretentive sustained-release formulation by combination of swelling and mucoadhesive approach: A mechanistic study. Drug Des Devel Ther 7. https://doi.org/10.2147/DDDT.S52890
27. Chatterjee B et al.,(2017). Mucoadhesive polymers and their mode of action: A recent update. J Appl Pharm Sci 7. https://doi.org/10.7324/JAPS.2017.70533.